SPOKE 1
Data and technology driven diagnosis and therapies
Data and technologies supporting diagnostic decisions and the development of personalized therapies.
Partner
SPOKE LEADER
Fabio Previdi
Università degli Studi di Bergamo
Objectives
- Development of digital solutions (hardware and software) to enable early and accurate diagnosis and meet the real therapeutic needs of chronic patients.
- Generation of the ideal experimental conditions to be able to manage together the omic and bioptic data in a functional and effective flow. The organization of the Spoke includes the collection of wet data (i.e., -omic and bioptic data) and their use connected to the information about the entire patient management process (from triage to therapeutic plan).
Methodologies
Spoke 1 is designed to process project results, making data from advanced technologies available for the diagnosis of tumours and chronic diseases. The objectives of the Spoke will be achieved by using the following methodologies.
Development of algorithms and models to extract diagnostic information from heterogeneous clinical data and to optimize and simplify the treatment of chronic diseases (clinical data science)
Clinical data management systems and integration of heterogeneous clinical databases, including genetic data (clinical data management).
Development of prototypes of systems and technologies to support diagnostics - from digital triage guided by AI to digital histology of tissues - and therapies for chronic diseases, from artificial pancreas to rare or infantile genetic diseases (technology driven diagnosis and therapies).
Spoke 1
Pilot-Based Programme
Pilot 1.1
It makes available to the other pilots the methodologies for analysis and management of clinical data of any nature.
Pilot 1.2 and 1.3
They are dedicated to the management and processing of data obtained from the therapeutic path starting from the clinical and care experience of the patient.
Pilot 1.4-1.5-1.6-1.7-1.8
They are dedicated to collecting and re-engineering genomic, proteomic, imaging and bioptic data obtained in the diagnostic pathways.
Pilot 1.3 and 1.8
They are dedicated to the development of new technological tools, both for personalized therapy of chronic insulin-dependent diabetes and for histological diagnosis through 3D reconstruction of tissues through high contrast microCT.
Pilot 1.4 and 1.7
They will use genetic data for the diagnosis of rare diseases and will provide a basis for the development of systems to manage genetic data and integrate them with traditional diagnostic methods.
Pilot 1.5 and 1.6
They will use AI techniques for cancer diagnosis and surgical therapy, the first using MALDI mass spectrometry imaging to obtain early molecular markers and the second through data fusion of heterogeneous image sources to support surgical therapy of a wide range of cancer pathologies.
SPOKE 1
Contacts
